MedTech Market Access Trends in 2022: Embracing Change and Dealing with It
MedTech Market Access Trends in 2022: Embracing Change and Dealing with It
Sponsored by:
Sponsored by:
More from Drug Pricing
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program
• By
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
• By
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
• By
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
• By
EFPIA says reforms make the continent less attractive for innovative firms.
More from Scrip
In partnership with
Learn more about the challenges faced by today’s drug developers and the critical factors to consider as sponsors navigate the supply chain, keep up with regulatory requirements, and ensure patient access. Discover more about the role of generics and how Aspire Pharma can help.
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
In partnership with
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development